schliessen

Filtern

 

Bibliotheken

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacothera... Full description

Journal Title: European Child & Adolescent Psychiatry 2011-04, Vol.20 (4), p.173-196
Main Author: Roessner, Veit
Other Authors: Plessen, Kerstin J , Rothenberger, Aribert , Ludolph, Anea G , Rizzo, Renata , Skov, Liselotte , Strand, Gerd , Stern, Jeremy S , Termine, Cristiano , Hoekstra, Pieter J
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer-Verlag
ID: ISSN: 1018-8827
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3065650
title: European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
format: Article
creator:
  • Roessner, Veit
  • Plessen, Kerstin J
  • Rothenberger, Aribert
  • Ludolph, Anea G
  • Rizzo, Renata
  • Skov, Liselotte
  • Strand, Gerd
  • Stern, Jeremy S
  • Termine, Cristiano
  • Hoekstra, Pieter J
subjects:
  • Antipsychotic Agents - therapeutic use
  • Article
  • ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
  • Behavioral health care
  • BOTULINUM TOXIN INJECTION
  • Care and treatment
  • Child and Adolescent Psychiatry
  • Child Health
  • DEFICIT-HYPERACTIVITY DISORDER
  • DOUBLE-BLIND
  • Europe
  • Guidelines
  • Human health
  • Human health and pathology
  • Humans
  • Life Sciences
  • LONG-TERM TREATMENT
  • Medical colleges
  • Medicine
  • Medicine & Public Health
  • Mental health
  • Narcolepsy
  • OBSESSIVE-COMPULSIVE DISORDER
  • Online health care information services
  • pathology
  • Pediatrics
  • Perinatology
  • Pharmacologic
  • Pharmacology
  • PLACEBO-CONTROLLED TRIAL
  • Practice guidelines (Medicine)
  • Psychiatry
  • RETROSPECTIVE CASE-NOTE
  • SIMPLE MOTOR TICS
  • Tic Disorders - drug therapy
  • Tics
  • Tourette
  • Tourette Syndrome - drug therapy
  • Tourette's syndrome
  • TRANSDERMAL NICOTINE
  • Treatment
  • Treatment methods
  • UMCG Approved
  • Working groups
ispartof: European Child & Adolescent Psychiatry, 2011-04, Vol.20 (4), p.173-196
description: To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.
language: eng
source:
identifier: ISSN: 1018-8827
fulltext: no_fulltext
issn:
  • 1018-8827
  • 1435-165X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6852849
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3065650
sourceformatXML
sourcesystemPC
galeidA252632126
sourcerecordidA252632126
originalsourceidFETCH-LOGICAL-1761t-2a39bfe887679c9e3209573736dd934851ba0f6d459046a22c6cff82b1c13fec0
addsrcrecordideNqFkl9r1jAUxosobk4_gDdS9EK86EzSNkm9EMaYbjDUiwmCFyFNTt43o2_yLmkn-_ae2jndkEnpn7TP8-vJOU9RPKdknxIi3ma8SFERSvHkdSUeFLu0qduK8vbbQ3wmVFZSMrFTPMn5nBDadoQ9LnYYbZpWsGa3CEdTilvQoTSDD97ooVxN3gIuIJcupvIsTgnGEcp8FWyKGyh1sGUc15DK0ZvS-hyThZT3yy86jeXJybtyu9Zpo00c4uoXckygxw2E8WnxyOkhw7Pr-17x9cPR2eFxdfr548nhwWlFBadjxXTd9Q6kFFx0poOaka4Vtai5tV3dyJb2mjhuG9xPwzVjhhvnJOupobUDQ_aK9wt3O_UbsAZ_nfSgtslvdLpSUXt1-0vwa7WKl6omvOUtQcCnBYDNCdonuOW1AUZlwU5b9cMp7KsitjO9NIyYRjhLetn1BGTXmrruG8c6BL5ZgOs7dRwfnKr5HSFc1i2hlxS1r6-rT_Figjyqjc8GhkEHiFNWHZGEEUnb_yol56xF6byhl3eU5zjYgENQspUdlZgIFL1aRCs9gPLBRWyOmZHqADm8ZpRxVO3_Q4WHhY03MYDz-P6WgS4Gk2LOCdxNAyhRc5LVkmSFSVZzkpVAz4u_J3jj-B1dFIg7UONHPfo4D9QP96LZ4swIDStIf1pxn-n7Ygo6GZ9v6knT6jpOmJF5EYY5WgPmfq4FkZo6LkSrAICpBnSjes2ZAmyP7jHetWzIT-oCLl0
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid858918445
display
typearticle
titleEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
creatorRoessner, Veit ; Plessen, Kerstin J ; Rothenberger, Aribert ; Ludolph, Anea G ; Rizzo, Renata ; Skov, Liselotte ; Strand, Gerd ; Stern, Jeremy S ; Termine, Cristiano ; Hoekstra, Pieter J
creatorcontribRoessner, Veit ; Plessen, Kerstin J ; Rothenberger, Aribert ; Ludolph, Anea G ; Rizzo, Renata ; Skov, Liselotte ; Strand, Gerd ; Stern, Jeremy S ; Termine, Cristiano ; Hoekstra, Pieter J ; ESSTS Guidelines Group ; the ESSTS Guidelines Group
descriptionTo develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.
identifier
0ISSN: 1018-8827
1EISSN: 1435-165X
2DOI: 10.1007/s00787-011-0163-7
3PMID: 21445724
4CODEN: EAPSE9
languageeng
publisherBerlin/Heidelberg: Springer-Verlag
subjectAntipsychotic Agents - therapeutic use ; Article ; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER ; Behavioral health care ; BOTULINUM TOXIN INJECTION ; Care and treatment ; Child and Adolescent Psychiatry ; Child Health ; DEFICIT-HYPERACTIVITY DISORDER ; DOUBLE-BLIND ; Europe ; Guidelines ; Human health ; Human health and pathology ; Humans ; Life Sciences ; LONG-TERM TREATMENT ; Medical colleges ; Medicine ; Medicine & Public Health ; Mental health ; Narcolepsy ; OBSESSIVE-COMPULSIVE DISORDER ; Online health care information services ; pathology ; Pediatrics ; Perinatology ; Pharmacologic ; Pharmacology ; PLACEBO-CONTROLLED TRIAL ; Practice guidelines (Medicine) ; Psychiatry ; RETROSPECTIVE CASE-NOTE ; SIMPLE MOTOR TICS ; Tic Disorders - drug therapy ; Tics ; Tourette ; Tourette Syndrome - drug therapy ; Tourette's syndrome ; TRANSDERMAL NICOTINE ; Treatment ; Treatment methods ; UMCG Approved ; Working groups
ispartofEuropean Child & Adolescent Psychiatry, 2011-04, Vol.20 (4), p.173-196
rights
0info:eu-repo/semantics/restrictedAccess
1The Author(s) 2011
2COPYRIGHT 2011 Springer
3Springer-Verlag 2011
4Distributed under a Creative Commons Attribution 4.0 International License
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1761t-2a39bfe887679c9e3209573736dd934851ba0f6d459046a22c6cff82b1c13fec0
citesFETCH-LOGICAL-1761t-2a39bfe887679c9e3209573736dd934851ba0f6d459046a22c6cff82b1c13fec0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21445724$$D View this record in MEDLINE/PubMed
1$$Uhttps://hal.archives-ouvertes.fr/hal-00683501$$DView record in HAL
search
creatorcontrib
0Roessner, Veit
1Plessen, Kerstin J
2Rothenberger, Aribert
3Ludolph, Anea G
4Rizzo, Renata
5Skov, Liselotte
6Strand, Gerd
7Stern, Jeremy S
8Termine, Cristiano
9Hoekstra, Pieter J
10ESSTS Guidelines Group
11the ESSTS Guidelines Group
title
0European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
1European Child & Adolescent Psychiatry
addtitle
0Eur Child Adolesc Psychiatry
1Eur Child Adolesc Psychiatry
descriptionTo develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.
subject
0Antipsychotic Agents - therapeutic use
1Article
2ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
3Behavioral health care
4BOTULINUM TOXIN INJECTION
5Care and treatment
6Child and Adolescent Psychiatry
7Child Health
8DEFICIT-HYPERACTIVITY DISORDER
9DOUBLE-BLIND
10Europe
11Guidelines
12Human health
13Human health and pathology
14Humans
15Life Sciences
16LONG-TERM TREATMENT
17Medical colleges
18Medicine
19Medicine & Public Health
20Mental health
21Narcolepsy
22OBSESSIVE-COMPULSIVE DISORDER
23Online health care information services
24pathology
25Pediatrics
26Perinatology
27Pharmacologic
28Pharmacology
29PLACEBO-CONTROLLED TRIAL
30Practice guidelines (Medicine)
31Psychiatry
32RETROSPECTIVE CASE-NOTE
33SIMPLE MOTOR TICS
34Tic Disorders - drug therapy
35Tics
36Tourette
37Tourette Syndrome - drug therapy
38Tourette's syndrome
39TRANSDERMAL NICOTINE
40Treatment
41Treatment methods
42UMCG Approved
43Working groups
issn
01018-8827
11435-165X
fulltextfalse
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFkl9r1jAUxosobk4_gDdS9EK86EzSNkm9EMaYbjDUiwmCFyFNTt43o2_yLmkn-_ae2jndkEnpn7TP8-vJOU9RPKdknxIi3ma8SFERSvHkdSUeFLu0qduK8vbbQ3wmVFZSMrFTPMn5nBDadoQ9LnYYbZpWsGa3CEdTilvQoTSDD97ooVxN3gIuIJcupvIsTgnGEcp8FWyKGyh1sGUc15DK0ZvS-hyThZT3yy86jeXJybtyu9Zpo00c4uoXckygxw2E8WnxyOkhw7Pr-17x9cPR2eFxdfr548nhwWlFBadjxXTd9Q6kFFx0poOaka4Vtai5tV3dyJb2mjhuG9xPwzVjhhvnJOupobUDQ_aK9wt3O_UbsAZ_nfSgtslvdLpSUXt1-0vwa7WKl6omvOUtQcCnBYDNCdonuOW1AUZlwU5b9cMp7KsitjO9NIyYRjhLetn1BGTXmrruG8c6BL5ZgOs7dRwfnKr5HSFc1i2hlxS1r6-rT_Figjyqjc8GhkEHiFNWHZGEEUnb_yol56xF6byhl3eU5zjYgENQspUdlZgIFL1aRCs9gPLBRWyOmZHqADm8ZpRxVO3_Q4WHhY03MYDz-P6WgS4Gk2LOCdxNAyhRc5LVkmSFSVZzkpVAz4u_J3jj-B1dFIg7UONHPfo4D9QP96LZ4swIDStIf1pxn-n7Ygo6GZ9v6knT6jpOmJF5EYY5WgPmfq4FkZo6LkSrAICpBnSjes2ZAmyP7jHetWzIT-oCLl0
startdate201104
enddate201104
creator
0Roessner, Veit
1Plessen, Kerstin J
2Rothenberger, Aribert
3Ludolph, Anea G
4Rizzo, Renata
5Skov, Liselotte
6Strand, Gerd
7Stern, Jeremy S
8Termine, Cristiano
9Hoekstra, Pieter J
general
0Springer-Verlag
1Springer
2Springer Nature B.V
3Springer Verlag (Germany)
4HAL CCSD
scope
05DI
15DJ
2QVL
3CGR
4CUY
5CVF
6ECM
7EIF
8NPM
9AAYXX
10CITATION
11BSHEE
120-V
133V.
147QJ
157RV
167TK
177X7
187XB
1988E
2088G
2188J
228AO
238FI
248FJ
258FK
268G5
27ABUWG
28ALSLI
29AZQEC
30BENPR
31DWQXO
32FYUFA
33GHDGH
34GNUQQ
35GUQSH
36HEHIP
37K9-
38K9.
39KB0
40M0R
41M0S
42M1P
43M2M
44M2O
45M2R
46M2S
47MBDVC
48NAPCQ
49PADUT
50PQEST
51PQQKQ
52PQUKI
53PRINS
54Q9U
557X8
561XC
57VOOES
58BOBZL
59CLFQK
605PM
sort
creationdate201104
titleEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
authorRoessner, Veit ; Plessen, Kerstin J ; Rothenberger, Aribert ; Ludolph, Anea G ; Rizzo, Renata ; Skov, Liselotte ; Strand, Gerd ; Stern, Jeremy S ; Termine, Cristiano ; Hoekstra, Pieter J
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1761t-2a39bfe887679c9e3209573736dd934851ba0f6d459046a22c6cff82b1c13fec0
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Antipsychotic Agents - therapeutic use
1Article
2ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
3Behavioral health care
4BOTULINUM TOXIN INJECTION
5Care and treatment
6Child and Adolescent Psychiatry
7Child Health
8DEFICIT-HYPERACTIVITY DISORDER
9DOUBLE-BLIND
10Europe
11Guidelines
12Human health
13Human health and pathology
14Humans
15Life Sciences
16LONG-TERM TREATMENT
17Medical colleges
18Medicine
19Medicine & Public Health
20Mental health
21Narcolepsy
22OBSESSIVE-COMPULSIVE DISORDER
23Online health care information services
24pathology
25Pediatrics
26Perinatology
27Pharmacologic
28Pharmacology
29PLACEBO-CONTROLLED TRIAL
30Practice guidelines (Medicine)
31Psychiatry
32RETROSPECTIVE CASE-NOTE
33SIMPLE MOTOR TICS
34Tic Disorders - drug therapy
35Tics
36Tourette
37Tourette Syndrome - drug therapy
38Tourette's syndrome
39TRANSDERMAL NICOTINE
40Treatment
41Treatment methods
42UMCG Approved
43Working groups
toplevelpeer_reviewed
creatorcontrib
0Roessner, Veit
1Plessen, Kerstin J
2Rothenberger, Aribert
3Ludolph, Anea G
4Rizzo, Renata
5Skov, Liselotte
6Strand, Gerd
7Stern, Jeremy S
8Termine, Cristiano
9Hoekstra, Pieter J
10ESSTS Guidelines Group
11the ESSTS Guidelines Group
collection
0NARCIS
1NARCIS: Datasets
2NARCIS:Publications
3Medline
4MEDLINE
5MEDLINE (Ovid)
6MEDLINE
7MEDLINE
8PubMed
9CrossRef
10Academic OneFile (A&I only)
11ProQuest Social Sciences Premium Collection
12ProQuest Central (Corporate)
13Applied Social Sciences Index & Abstracts (ASSIA)
14Nursing & Allied Health Database
15Neurosciences Abstracts
16Health & Medical Collection
17ProQuest Central (purchase pre-March 2016)
18Medical Database (Alumni Edition)
19Psychology Database (Alumni)
20Social Science Database (Alumni Edition)
21ProQuest Pharma Collection
22Hospital Premium Collection
23Hospital Premium Collection (Alumni Edition)
24ProQuest Central (Alumni) (purchase pre-March 2016)
25Research Library (Alumni Edition)
26ProQuest Central (Alumni Edition)
27Social Science Premium Collection
28ProQuest Central Essentials
29ProQuest Central
30ProQuest Central Korea
31Health Research Premium Collection
32Health Research Premium Collection (Alumni)
33ProQuest Central Student
34Research Library Prep
35Sociology Collection
36Consumer Health Database (Alumni Edition)
37ProQuest Health & Medical Complete (Alumni)
38Nursing & Allied Health Database (Alumni Edition)
39Consumer Health Database
40Health & Medical Collection (Alumni Edition)
41Medical Database
42Psychology Database
43Research Library
44Social Science Database
45Sociology Database
46Research Library (Corporate)
47Nursing & Allied Health Premium
48Research Library China
49ProQuest One Academic Eastern Edition
50ProQuest One Academic
51ProQuest One Academic UKI Edition
52ProQuest Central China
53ProQuest Central Basic
54MEDLINE - Academic
55Hyper Article en Ligne (HAL)
56Hyper Article en Ligne (HAL) (Open Access)
57OpenAIRE (Open Access)
58OpenAIRE
59PubMed Central (Full Participant titles)
jtitleEuropean Child & Adolescent Psychiatry
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Roessner, Veit
1Plessen, Kerstin J
2Rothenberger, Aribert
3Ludolph, Anea G
4Rizzo, Renata
5Skov, Liselotte
6Strand, Gerd
7Stern, Jeremy S
8Termine, Cristiano
9Hoekstra, Pieter J
aucorp
0ESSTS Guidelines Group
1the ESSTS Guidelines Group
formatjournal
genrearticle
ristypeJOUR
atitleEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
jtitleEuropean Child & Adolescent Psychiatry
stitleEur Child Adolesc Psychiatry
addtitleEur Child Adolesc Psychiatry
date2011-04
risdate2011
volume20
issue4
spage173
epage196
pages173-196
issn1018-8827
eissn1435-165X
codenEAPSE9
abstractTo develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.
copBerlin/Heidelberg
pubSpringer-Verlag
pmid21445724
doi10.1007/s00787-011-0163-7
oafree_for_read